Table 1 Comparison of clinicopathological characteristics between high and low mGNRI groups in patients with pancreatic cancer
Before propensity score matching | After propensity score matching | |||||
|---|---|---|---|---|---|---|
Characteristics | High mGNRI group | Low mGNRI group | P-value | High mGNRI group | Low mGNRI group | P-value |
(n = 91) | (n = 46) | (n = 36) | (n = 36) | |||
Age (years), median (range) | 72 (47–85) | 72.5 (44–85) | 0.616 | 72.5 (55–85) | 72.3 (44–85) | 0.795 |
Sex (male), n (%) | 51 (56%) | 30 (65.2%) | 0.302 | 20 (55.6%) | 21 (58.3%) | 0.812 |
Body mass index (kg/m2), median (range) | 22.7 (18.8–32.5) | 19.4 (13.7–29.4) | < 0.001 | 21.8 (18.9–30.0) | 20.2 (13.7–28.5) | 0.002 |
Tumor size (mm), median (range) | 27.0 (11.0–85.0) | 28.0 (5.0–60.0) | 0.791 | 25.8 (11.0–85.0) | 27.7 (5.0–60.0) | 0.676 |
Tumor location (pancreatic head), n (%) | 40 (44.0%) | 16 (34.8%) | 0.302 | 18 (50.0%) | 14 (38.9%) | 0.343 |
Histological grading (G2a or G3b), n (%) | 42 (46.2%) | 25 (54.3%) | 0.365 | 18 (50.0%) | 20 (55.6%) | 0.637 |
Lymph node involvement (present), n (%) | 44 (48.4%) | 36 (78.3%) | 0.001 | 26 (72.2%) | 26 (72.2%) | 1.000 |
Residual tumor (present), n (%) | 10 (11.0%) | 3 (6.5%) | 0.543 | 3 (8.3%) | 1 (2.8%) | 0.614 |
ASA-PS (1 or 2, %) | 78 (85.7%) | 33 (71.7%) | 0.065 | 31 (86.1%) | 27 (75.0%) | 0.234 |
Preoperative albumin, g/dL, median (range) | 4.1 (2.6–4.9) | 3.8 (2.1–4.9) | 0.001 | 4.1 (3.3–4.8) | 3.9 (2.7–4.9) | 0.039 |
Preoperative lymphocyte count, median (range) | 1640 (140–3800) | 1405 (400–6660) | 0.004 | 1740 (140–3016) | 1389 (735–2496) | 0.037 |
Preoperative CA19-9, U/mL, median (range) | 53.3 (0.7–3270.7) | 106.7 (0.7–3435.0) | 0.121 | 58.9 (1.1–1591.6) | 61.0 (0.7–1446.5) | 0.875 |
Neoadjuvant chemotherapy (present), n (%) | 15 (16.5%) | 4 (8.7%) | 0.297 | 2 (5.6%) | 4 (11.1%) | 0.674 |
Adjuvant chemotherapy (present), n (%) | 52 (59.1%) | 28 (60.9%) | 0.842 | 23 (63.9%) | 21 (58.3%) | 0.629 |